LPCN Stock: Lipocine Inc. Stock Price, Analysis & Insights
Get live lpcn stock price $8.03, comprehensive Lipocine Inc. stock analysis, charts, news, and expert forecast. Real-time lpcn stock data and investment insights.
Loading chart...
Company Overview
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Company Information
- CEO
- Mahesh V. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
Contact Information
- Website
- https://www.lipocine.com
- Address
- 675 Arapeen Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Lipocine Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Mahesh V. Patel, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Lipocine Inc. competes in the Biotechnology within the broader Healthcare. With 43.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Lipocine Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Lipocine Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Lipocine Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Lipocine Inc.
- ⚠Investors should consider how Lipocine Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
43.07M
P/E Ratio
-7.87
Beta
1.03
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 43.07M market capitalization
- Trading Volume: 414.19K shares traded today
- Price Range: 52-week range of $2.52 - $8.29
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Lipocine Inc.
Lipocine Inc. (LPCN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 43.07M, the company represents a significant player in its market. The stock is currently trading at $8.03 with a positivedaily change of 22.22%.
The company's 16 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.87, beta of 1.03, and 52-week price range from $2.52 to $8.29when evaluating investment opportunities.
Why Invest in Lipocine Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Mahesh V. Patel
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.